• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Reduced bleeding risk with asundexian compared to apixaban in patients with atrial fibrillation

byNeel MistryandTeddy Guo
April 19, 2022
in Cardiology, Chronic Disease, Hematology, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Asundexian 50 mg resulted in a lower rate of bleeding compared to apixaban 5 mg twice daily.

2. The rate of adverse events in all three treatment groups was comparable.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Direct oral anticoagulants (DOACs) are recommended as first-line therapy in patients with atrial fibrillation with risk factors for thromboembolic events, such as a stroke. However, a major concern with DOACs is the risk of bleeding. Asundexian is an oral factor XIa inhibitor that may decrease the risk of bleeding without affecting hemostasis, compared with DOAC therapy. This randomized double-blind trial aimed to compare the safety and efficacy of asundexian with that of apixaban in patients with atrial fibrillation. Patients were assigned to one of three treatment groups: asundexian 20 mg once daily, asundexian 50 mg once daily, or apixaban 5 mg twice daily. The primary outcome was the risk of major or non-major bleeding as per the International Society on Thrombosis and Hemostasis (ISTH) criteria, while key secondary outcomes included all types of bleeding. According to study results, patients assigned to asundexian 20 mg and 50 mg reported lower risk of bleeding compared to apixaban 5 mg twice daily. The incidence of adverse events was similar between all groups. This study was strengthened by a double-blind design with patients from various countries which increases the generalizability of findings.

Click to read the study in The Lancet

Relevant Reading: Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer

In-depth [randomized-controlled trial]: Between Jan 30, 2020, and Jun 21, 2021, 862 patients were enrolled across 93 sites in Europe, Canada, and Japan. Included were those aged ≥ 45 years with atrial fibrillation, a CHA2DS2-VASc ≥ 2 if male or ≥ 3 if female, and high bleeding risk. Altogether, 753 patients (249 to asundexian 20 mg, 254 to asundexian 50 mg, and 250 to apixaban 5 mg twice daily) were included in the analysis. Mean patient age was 73.7 years (standard deviation [SD] 8.3) with an average CHA2DS2-VASc score of 3.9 (SD 1.3). The primary outcome of bleeding was lower in the asundexian group (asundexian 20 mg: incidence proportion [IP] 0.50, 95% confidence interval [CI] 0.14-1.68; asundexian 50 mg: IP 0.16, 95% CI 0.01-0.99) compared to apixaban (pooled asundexian: IP 0.33, 90% CI 0.09-0.97). At peak concentrations, asundexian 50 mg resulted in greater inhibition of Factor XIa activity than asundexian 20 mg (94% vs. 90%). Furthermore, all three intervention groups had comparable adverse events (47% with asundexian 20 mg and 50 mg, and 49% with apixaban 5 mg twice daily). Overall, findings from this study suggest that asundexian decreases the rate of bleeding compared to apixaban in patients with atrial fibrillation.

RELATED REPORTS

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

Empagliflozin use is associated with slower progression of chronic kidney disease

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: apixabanasundexianatrial fibrillationcardiologydirect oral anticoagulant (DOAC)DOAChematologyneurologystrokestroke risk
Previous Post

Childhood insomnia symptoms may persist into adulthood

Next Post

Familial natural short sleep mutations may reduce Alzheimer’s Disease pathology in mice [PreClinical]

RelatedReports

β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

January 27, 2023
Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

January 27, 2023
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
#VisualAbstract: Addition of posterior wall isolation to pulmonary vein isolation did not increase resolution of atrial fibrillation
StudyGraphics

#VisualAbstract: Addition of posterior wall isolation to pulmonary vein isolation did not increase resolution of atrial fibrillation

January 17, 2023
Next Post
Abusive head trauma results in fewer productive life-years

Familial natural short sleep mutations may reduce Alzheimer’s Disease pathology in mice [PreClinical]

Women electing abortion more likely to be victims of domestic violence

Prenatal exposure to maternal autoimmune diseases associated with increased risks of mental disorders in offspring

Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact

Radiofrequency renal denervation produces long-lasting reductions in blood pressure

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options